Carolyn C. Tang is CLO at Arcus Biosciences, Inc. (RCUS). They have made 5 open-market trades across 1 company since 2021, most recently 2026-06-11.
CIK 0001836662
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RCUS | 184,607 | $4.1M |
Shares reported on the most recent Form 4, priced at the 2026-06-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RCUS | SELL | 2025-12-16 | 2025-12-18 | $22.01 | $637K | +8.4% | -0.1% | +1.0% |
| RCUS | SELL | 2022-12-16 | 2022-12-16 | $30.71 | $143K | -33.9% | -33.7% | -44.7% |
| RCUS | SELL | 2022-06-16 | 2022-06-21 | $21.45 | $63K | +16.7% | +26.1% | +12.5% |
| RCUS | SELL | 2021-12-16 | 2021-12-20 | $40.12 | $44K | -1.3% | -18.3% | -15.6% |
| RCUS | SELL | 2021-06-16 | 2021-06-21 | $23.89 | $70K | +19.0% | +37.1% | +51.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.